Oculis (NASDAQ:OCS) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.

Investment analysts at JPMorgan Chase & Co. started coverage on shares of Oculis (NASDAQ:OCS) in a report issued on Friday,Benzinga reports. The brokerage set an “overweight” rating and a $38.00 price target on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 95.07% from the company’s previous close.

OCS has been the topic of several other research reports. Lifesci Capital started coverage on Oculis in a research note on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 target price on the stock. Bank of America cut their price objective on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Wall Street Zen upgraded shares of Oculis from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Chardan Capital reiterated a “buy” rating and issued a $51.00 price target on shares of Oculis in a research note on Tuesday, November 11th. Finally, HC Wainwright boosted their price target on shares of Oculis from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Oculis presently has a consensus rating of “Moderate Buy” and an average target price of $41.71.

Oculis Price Performance

Shares of NASDAQ OCS opened at $19.48 on Friday. The company has a fifty day moving average price of $20.10 and a 200 day moving average price of $18.85. The firm has a market cap of $1.02 billion, a PE ratio of -7.73 and a beta of 0.32. The company has a current ratio of 4.47, a quick ratio of 4.47 and a debt-to-equity ratio of 0.02. Oculis has a 1-year low of $14.00 and a 1-year high of $23.08.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.23 million. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%. Research analysts predict that Oculis will post -2.09 earnings per share for the current fiscal year.

Institutional Trading of Oculis

Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its holdings in shares of Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after purchasing an additional 878 shares during the period. Geode Capital Management LLC grew its holdings in Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after purchasing an additional 6,384 shares during the period. Compagnie Lombard Odier SCmA increased its position in Oculis by 11.5% during the second quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock worth $1,883,000 after buying an additional 10,000 shares during the last quarter. Bosun Asset Management LLC bought a new stake in Oculis in the second quarter valued at approximately $378,000. Finally, Marshall Wace LLP acquired a new stake in shares of Oculis in the second quarter valued at approximately $393,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.